Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss

Audiology and Neurotology

Volumn 14, Issue 6, 2009, Pages 423-431

  Trune, Dennis R ^a   Kempton, J Beth ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Autoimmune inner ear disease; Autoimmune mice; Inner ear; Prednisolone; RU 486; Steroid receptors

Indexed keywords

ANALYSIS OF VARIANCE; ANIMALS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; AUTOIMMUNE DISEASES; COCHLEA; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GLUCOCORTICOIDS; HEARING LOSS; HORMONE ANTAGONISTS; MICE; MICE, TRANSGENIC; MIFEPRISTONE; PREDNISOLONE; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; TIME FACTORS;

EID: 70450188096     PISSN: 14203030     EISSN: 14219700     Source Type: Journal    
DOI: 10.1159/000241899     Document Type: Article

References (62)

1. Dornhoffer JL, Arenberg JG, Arenberg IK, Shambaugh GE Jr: Pathophysiological mechanisms in immune inner ear disease. Acta Otolaryngol (Stockh) 1997;Suppl 526: 30-36.
2. Alexiou C, Arnold W, Fauser C, Schratzenstaller B, Gloddek B, Fuhrmann S, Lamm K: Sudden sensorineural hearing loss: Does application of glucocorticoids make sense? Arch Otolaryngol Head Neck Surg 2001; 127: 253-258.
3. Rauch SD: Intratympanic steroids for sensorineural hearing loss. Otolaryngol Clin North Am 2004; 37: 1061-1074.
4. Aoki D, Takegoshi H, Kikuchi S: Evaluation of super-high-dose steroid therapy for sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2006; 134: 783-787.
5. Barrs DM: Intratympanic corticosteroids for Meniere's disease and vertigo. Otolaryngol Clin North Am 2004; 37: 955-972.
6. Niparko JK, Wang N-Y, Rauch SD, Russell GB, Espeland MA, Pierce JJ, Bowditch S, Masuda A, Gulya AJ, Gantz BJ, Hughes GB, Brookhouser PE, Hannley MT, Telian SA, Harris JP, AIED Study Group: Serial audiometry in a clinical trial of AIED treatment. Otol Neurotol 2005; 26: 908-917.
7. Loveman DM, de Comarmond C, Cepero R, Baldwin DM: Autoimmune sensorineural hearing loss: Clinical course and treatment outcome. Sem Arthrit Rheumat 2004; 34: 538-543.
8. Smoak KA, Cidlowski JA: Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Age Develop 2004; 125: 697-706.
9. de Bosscher K, vanden Berghe W, Haegeman G: The interplay between the glucocorticoid receptor and nuclear factor-kB or activator protein-1: Molecular mechanisms for gene repression. Endocrin Rev 2003; 24: 488-522.
10. Ghaheri B, Kempton JB, Pillers DM, Trune DR: Cochlear cytokine gene expression in murine acute otitis media. Laryngoscope 2007; 117: 22-29.
11. Adams JC: Clinical implications of inflammatory cytokines in the cochlea: A technical note. Otol Neurotol 2002; 23: 316-322.
12. Nagashima R, Sugiyama C, Yoneyama M, Ogita K: Transcriptional factors in the cochlea within the ear. J Pharmacol Sci 2005; 99: 301-306.
13. Canlon B, Meltser I, Johansson P, Tahera Y: Glucocorticoid receptors modulate auditory sensitivity to acoustic trauma. Hear Res 2007; 226: 61-69.
14. Lee JH, Marcus DC: Nongenomic effects of corticosteroids on ion transport by stria vascularis. Audiol Neurootol 2002; 7: 100-106.
15. Pondugula SR, Sanneman JD, Wangemann P, Milhaud PG, Marcus DC: Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. Am J Physiol Renal Physiol 2004; 286:F1127-F1135.
16. Trune DR, Kempton JB, Gross ND: Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear Res 2006; 212: 22-32.
17. Trune DR: Ion homeostasis and inner ear diseases; in Hamid MA, Sismanis A (eds): Medical Otology and Neurotology: A Medical Guide to Auditory and Vestibular Disorders. New York, Thieme, 2006, pp 21-32.
18. Mouadeb DA, Ruckenstein MJ: Antiphospholipid inner ear syndrome. Laryngoscope 2005; 115: 879-883.
19. Barkhuizen A, Lim L, Trune D, Rosenbaum J: Ocular, aural, and oral manifestations; in Wallace DJ, Hahn BH (eds): Dubois' Lupus Erythematosus. Baltimore, Lippincott William & Wilkins, 2006, pp 789-800.
20. Mathews J, Kumar BN: Autoimmune sensorineural hearing loss. Clin Otolaryngol 2003; 28: 479-488.
21. Harris JP, Ryan AF: Fundamental immune mechanisms of the brain and inner ear. Otolaryngol Head Neck Surg 1995; 112: 639-653.
22. Barna BP, Hughes GB: Autoimmune inner ear disease - a real entity? Clin Lab Med 1997; 17: 581-594.
23. Yehudai D, Schoenfeld Y, Toubi E: The autoimmune characteristics of progressive or sudden sensorineural hearing loss. Autoimmunity 2006; 39: 153-158.
24. Garcia-Berrocal JR, Ramirez-Camacho R: Sudden sensorineural hearing loss: Supporting the immunologic theory. Ann Otol Rhinol Laryngol 2002; 111: 989-997.
25. Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004; 112: 169-174.
26. Pierangeli SS, Chen PP, González EB: Antiphospholipid antibodies and the antiphospholipid syndrome: An update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13: 366-375.
27. Hamid C, Norgate K, D'Cruz DP, Khamashta MA, Arno M, Pearson JD, Frampton G, Murphy JJ: Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007; 66: 1000-1007.
28. Pober JS, Sessa WC: Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7: 803-815.
29. Lin DW, Trune DR: Breakdown of stria vascularis blood-labyrinth barrier in C3H/lpr autoimmune disease mice. Otolaryngol Head Neck Surg 1997; 117: 530-534.
30. Ruckenstein MJ, Milburn M, Hu L: Strial dysfunction in the MRL-Fasl pr mouse. Otolaryngol Head Neck Surg 1999; 121: 452-456.
31. Hefeneider SH, McCoy SL, Hausman FA, Trune DR: Autoimmune mouse antibodies recognize multiple antigens proposed in human immune-mediated hearing loss. Otol Neurotol 2004; 25: 250-256.
32. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH: Steroid therapy improves cochlear function in the C3H.MRL-Fas lpr autoimmune mouse. Hear Res 1999; 137: 160-166.
33. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH: Steroid treatment in young MRL. MpJ-F asl pr autoimmune mice prevents cochlear dysfunction. Hear Res 1999; 137: 167-173.
34. Trune DR, Kempton JB: Aldosterone and prednisolone control of auditory dysfunction in MRL/MpJ-F asl pr autoimmune mice. Hear Res 2001; 155: 9-20.
35. Daynes RA, Araneo BA, Dowell TA, Huang K, Dudley D: Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990; 171: 979-996.
36. Zhao B, Chua SS, Burcin MM, Reynolds SD, Stripp BR, Edwards RA, Finegold MJ, Tsai SY, DeMayo FJ: Phenotypic consequences of lung-specific inducible expression of FGF-3. PNAS 2001; 98: 5898-5903.
37. Pierson TM, Wang Y, DeMayo FJ, Matzuk MM, Tsai SY, O'Malley BW: Regulable expression of inhibin A in wild-type and inhibin- null mice. Mol Endocrin 2000; 14: 1075-1085.
38. Mitchell CR, Kempton JB, Creedon TA, Trune DR: Using a 56-stimulus train for the rapid acquisition of auditory brainstem responses. Audiol Neurootol 1999; 4: 80-87.
39. Trune DR, Craven JP, Morton JI, Mitchell C: Autoimmune disease and cochlear pathology in C3H/lpr strain mouse. Hear Res 1989; 38: 57-66.
40. Furuta H, Mori N, Sato C, Hoshikawa H, Sakai S, Iwakura S, Doi K: Mineralocorticoid type I receptor in the rat cochlea: MRNA identification by polymerase chain reaction (PCR) and in situ hybridization. Hear Res 1994; 78: 175-180.
41. Yao X, Rarey KE: Localization of the mineralocorticoid receptor in rat cochlear tissue. Acta Otolaryngol 1996; 116: 493-496.
42. Shimazaki T, Ichimiya I, Suzuki M, Mogi G: Localization of glucocorticoid receptors in the murine inner ear. Ann Otol Rhinol Laryngol 2002; 111: 1133-1138.
43. Erichsen S, Bagger-Sjöbäck D, Curtis L, Zuo J, Rarey K, Hultcrantz M: Appearance of glucocorticoid receptors in the inner ear of the mouse during development. Acta Otolaryngol 1996; 116: 721-725.
44. Hargunani CA, DeGagne JM, Kempton JB, Trune DR: Inner ear uptake and distribution of dexamethasone injected into the middle ear. Otol Neurotol 2006; 27: 564-569.
45. Parnes LS, Sun A-H, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: An animal study followed by clinical application. Laryngoscope 1999;(suppl)91: 1-17.
46. Hahn H, Kammerer B, DiMauro A, Salt AN, Plontke SK: Cochlear microdialysis for quantification of dexamethasone and fluorescein entry into scala tympani during round window administration. Hear Res 2006; 212: 236-244.
47. Plontke SK, Siedow N, Wegener R, Zenner HP, Salt AN: Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurootol 2007; 12: 37-48.
48. Plontke SK, Biegner T, Kammerer B, Delabar U, Salt AN: Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008; 29: 401-406.
49. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connelly PE, Huang E, Bareded S: Dexamethasone pharmacokinetics in the inner ear: Comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000; 122: 521-528.
50. Claire M, Faraj H, Grassy G, Aumelas A, Rondot A, Auzou G: Synthesis of new 11--substituted spironolactone derivatives. Relationship with affinity for mineralocorticoid and glucocorticoid receptors. J Med Chem 1993; 36: 2404-2407.
51. Munck A, Mendel DB, Smith LI, Orti E: Glucocorticoid receptors and actions. Am Rev Respir Dis 1990; 141:S2-S10.
52. Rupprecht R, Reul JMHM, van Steensel B, Spengler D, Söder M, Berning B, Holsboer F, Damm K: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharm Mol Pharm 1993; 247: 145-154.
53. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM: Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-275.
54. Barnes PJ, Adcock I: Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharm Sci 1993; 14: 436-441.
55. Smith PJ, Cousins DJ, Jee Y-K, Staynov DZ, Lee TH, Lavender P: Suppression of granulocyte-macrophage colony-stimulating factor expression by glucocorticoids involves inhibition of enhancer function by the glucocorticoid receptor binding to composite NF-AT/ activator protein-1 elements. J Immunol 2001; 167: 2502-2510.
56. Funder JW: Glucocorticoid and mineralocorticoid receptors: Biology and clinical relevance. Ann Rev Med 1997; 48: 231-240.
57. Tadros SF, Frisina ST, Mapes F, Frisina DR, Frisina RD: Higher serum aldosterone correlates with lower hearing thresholds: A possible protective hormone against presbycusis. Hear Res 2005; 209: 10-18.
58. Conlin AE, Parnes LS: Treatment of sudden sensorineural hearing loss. II. A Meta-analysis. Arch Otolaryngol Head Neck Surg 2007; 133: 582-586.
59. Conlin AE, Parnes LS: Treatment of sudden sensorineural hearing loss. I. A systematic review. Arch Otolaryngol Head Neck Surg 2007; 133: 573-581.
60. Eisenman DJ, Arts HA: Effectiveness of treatment for sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2000; 126: 1161-1166.
61. Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB, Mason J, Maw J, Musiek FL: Intratympanic steroid treatment: A review. Otol Neurotol 2004; 25: 1034-1039.
62. Rahman MU, Poe DS, Choi HK: Autoimmune vestibulo-cochlear disorders. Curr Opin Rheumatol 2001; 13: 184-189.